Search results
Results From The WOW.Com Content Network
In epidemiology, case fatality rate (CFR) – or sometimes more accurately case-fatality risk – is the proportion of people who have been diagnosed with a certain disease and end up dying of it. Unlike a disease's mortality rate , the CFR does not take into account the time period between disease onset and death.
A patient with working heart and lungs who is determined to be brain dead can be pronounced legally dead without clinical death occurring. However, some courts have been reluctant to impose such a determination over the religious objections of family members, such as in the Jesse Koochin case. [ 30 ]
If all cancer patients survived and cancer occurred randomly, the normal lifetime odds of developing a second primary cancer (not the first cancer spreading to a new site) would be one in nine. [29] However, cancer survivors have an increased risk of developing a second primary cancer, and the odds in 2003 were about one in 4.5. [29]
A young patient with an “aggressive-looking” prostate cancer, whose father had the condition and who carries a BRCA2 mutation, is an entirely different patient from “an 80-year-old man who ...
Progression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". [1] In oncology, PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically. Similarly ...
For example, various Global Burden of Disease Studies investigate such factors and quantify recent developments – one such systematic analysis analyzed the (non)progress on cancer and its causes during the 2010–19-decade, indicating that 2019, ~44% of all cancer deaths – or ~4.5 M deaths or ~105 million lost disability-adjusted life years ...
In patients taking drugs for cancer, the likelihood of MRONJ development varies from 0 - 12%. This again, varies with the type of cancer, although prostate cancer and multiple myeloma are reported to be at a higher risk. [8] In patients taking oral drugs for osteoporosis, the likelihood of MRONJ development varies from 0 - 0.2%. [7]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!